Navigation Links
Dr. Lowell S. Kabnick First to Use New VenaCure® 1470nm Laser
Date:6/9/2011

MORRISTOWN, N.J., June 9, 2011 /PRNewswire/ -- Dr. Lowell S. Kabnick, MD, RPhS, FACS, FACPh, Director of NYU Vein Center and internationally recognized authority and pioneer in the field of vascular surgery, is once again leading the way with breakthrough techniques, being the first in the country to use the new VenaCure® 1470nm laser to treat varicose veins. The new laser uses a lower power output compared with other lasers resulting in effective vein closure.

The VenaCure 1470nm laser's light energy is accurately delivered through the NeverTouch® gold-tip fiber, and is more readily absorbed by the water in the blood and endothelial lining than with other wavelengths. The specially engineered fiber tip has a low power density that maximizes effectiveness and minimizes postoperative pain and bruising. The VenaCure 1470nm lasers are manufactured in AngioDynamics' Cambridge, U.K., facility, and have received the CE mark and 510k clearance.

Ongoing research studies have found excellent vein closure rates, minimal postoperative discomfort and bruising, and a clear reduction in symptom severity over the follow-up period.

"The 1470nm laser enables us to be more efficient during a procedure, we are able to treat veins much more efficiently, which ultimately improves the patients procedure experience," stated Dr. Kabnick. "That translates into quicker recovery for patients."

About Lowell S. Kabnick, MD, RPhS, FACS, FACPh

Lowell S. Kabnick, MD, RPhS, FACS, FACPh, a New York University Surgeon with offices in Manhattan and Morristown, NJ and Director of NYU Vein Center, is a world-renowned surgeon-teacher whose patient-centered approach to vein care has enabled the creation and improvement of many of today's most advanced noninvasive vascular surgery techniques. Recognized by his peers as an international leader in the diagnosis and treatment of venous disease, Dr. Kabnick was the first vascular surgeon in the United States to perform the VNUS Closure™ (radiofrequency) procedure and the VenaCure EVLT® (laser) procedure - two FDA-approved breakthrough technologies for treating the underlying causes of many varicose vein problems. For more information, please visit www.lowellkabnickmd.com.

Contact:
Lowell S. Kabnick, MD, RPhS, FACS, FACPh, lowell.kabnick@nyumc.org

New Jersey:
95 Madison Ave
Suite 415
Morristown, NJ 07960
Phone: 973-538-2000

New York:
NYU Vein Center
530 First Avenue
Suite 6D
New York, NY 10016
Phone: 212-263-8346


'/>"/>
SOURCE Lowell S. Kabnick
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alzheimers Association Grant Furthers Successful Research at UMass Lowell
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
4. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Tainted Chinese Food Ingredients First Discovered in 2005
9. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - 2016, provides ... research answers the following questions: What are ... they positioned in the Global Menopause market? What are ...
(Date:2/23/2017)... , Feb. 23, 2017 Research and ... Analysis and Strategies - 2016" report to their offering. ... The latest research ... data and benchmarks in the global Fibromyalgia market. The ... the key drugs marketed for Fibromyalgia and their clinical attributes? How ...
(Date:2/23/2017)... 23, 2017 Obese people are ... for varicose veins in their body. The rising number ... the adoption of endovenous laser therapy for treatment of ... laser therapy market, published by Future Market Insights, ... and consequences of obesity have collectively factored the growth ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... Congratulations to Head Over Heels’ elite ... 12th. Ms. Esparza qualified into this prestigious status after winning the Vault, ... Vegas, Nevada. Frida is one of approximately 25 gymnasts in the nation who ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
(Date:2/23/2017)... CO (PRWEB) , ... February 23, 2017 , ... The ... announce the winner of the 2016 National Education Policy Center Bunkum Award. We invite ... reviewed in 2016. , This year’s Bunkum winner is the Center for American Progress ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease ... will be participating in Rare Disease Day events, hosted by the Rare Disease ... Disease Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews ...
(Date:2/23/2017)... Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... first two episodes of WE TV’s “Mama June: From Not to Hot,” which will ... TV notable, “Mama” June Shannon, known to millions from the 2012 reality television series, ...
Breaking Medicine News(10 mins):